This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/chemspider/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/chebi/
n11http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/pharmgkb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/kegg-compound/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n16http://www.rxlist.com/cgi/generic2/
n8http://linked.opendata.cz/resource/drugbank/property/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00521/identifier/drugbank/
n22http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00521
rdf:type
n3:Drug
n3:description
A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. [PubChem]
n3:dosage
n13:271B64EB-363D-11E5-9242-09173F13E4C5 n13:271B64EC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# El-Kamel A, Al-Dosari H, Al-Jenoobi F: Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16401594 # Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A: Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea. 2005 Mar;24(2):213-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15725891 # Trinquand C, Romanet JP, Nordmann JP, Allaire C: [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study] J Fr Ophtalmol. 2003 Feb;26(2):131-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12660585
n3:group
approved
n3:indication
For the treatment of intraocular hypertension and chronic open-angle glaucoma
n3:manufacturer
n4:271B64E4-363D-11E5-9242-09173F13E4C5 n4:271B64E2-363D-11E5-9242-09173F13E4C5 n4:271B64E3-363D-11E5-9242-09173F13E4C5 n4:271B64E0-363D-11E5-9242-09173F13E4C5 n4:271B64E1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00521 n11:DB00521
dcterms:title
Carteolol
adms:identifier
n6:46507513 n12:Carteolol n14:PA164768736 n23:2485 n24:DB00521 n25:3437 n26:2583 n27:C06874 n28:58768-001-01
n3:mechanismOfAction
The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade.
n3:packager
n4:271B64DF-363D-11E5-9242-09173F13E4C5 n4:271B64DC-363D-11E5-9242-09173F13E4C5 n4:271B64DD-363D-11E5-9242-09173F13E4C5 n4:271B64DA-363D-11E5-9242-09173F13E4C5 n4:271B64DB-363D-11E5-9242-09173F13E4C5 n4:271B64D8-363D-11E5-9242-09173F13E4C5 n4:271B64D9-363D-11E5-9242-09173F13E4C5 n4:271B64D7-363D-11E5-9242-09173F13E4C5 n4:271B64DE-363D-11E5-9242-09173F13E4C5
n3:synonym
Carteolol Carteololum
n3:toxicity
The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.
n3:salt
n3:synthesisReference
Tamura,Y., Nakagawa,K., Yoshizaki,S.and Murakami,N.; U.S.Patent 3,910,924; October 7, 1975; assigned to Otsuka Pharmaceutical Co., Ltd.
n18:hasConcept
n19:M0003563
foaf:page
n16:carteol.htm n17:carteolol-drops.html
n3:IUPAC-Name
n8:271B64F1-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B64F7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B64F6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B64F3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B64F4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B64F5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B64EF-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B64F0-363D-11E5-9242-09173F13E4C5 n8:271B6507-363D-11E5-9242-09173F13E4C5 n8:271B64ED-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B64EE-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:S01ED05 n22:C07AA15
n3:H-Bond-Acceptor-Count
n8:271B64FD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B64FE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B64F8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B64F9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B64FB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B64FA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B64FC-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51781-06-7
n3:category
n3:containedIn
n7:271B64E9-363D-11E5-9242-09173F13E4C5 n7:271B64EA-363D-11E5-9242-09173F13E4C5 n7:271B64E7-363D-11E5-9242-09173F13E4C5 n7:271B64E8-363D-11E5-9242-09173F13E4C5 n7:271B64E5-363D-11E5-9242-09173F13E4C5 n7:271B64E6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B6503-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B6505-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B6506-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B6502-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B6501-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B6504-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B64F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B64FF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B6500-363D-11E5-9242-09173F13E4C5